Pathward Secures a Spot on the 2025 Monitor 100
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250724956436/en/
Pathward has earned a spot on the 2025 Monitor 100 list. The annual Monitor 100 rankings recognize and celebrate the top equipment finance and leasing organizations across the nation based on portfolio activity and volume of business each year.
'We're honored to be recognized on the Monitor 100 list for the 13th year in a row,' said Christopher Soupal, Divisional President and Revenue Lending Officer at Pathward. 'Being named to the annual list of top equipment finance companies is a testament to our team that is dedicated to Pathward's purpose of financial inclusion and providing funding solutions to help businesses reach their goals.'
Read Pathward's feature on page 28 in the Monitor 100 2025 | Vol. 52 No. 4.
In addition to Equipment Finance solutions, Pathward offers Working Capital and Structured Finance solutions as part of our forward-thinking Commercial Finance portfolio. Learn more about our flexible finance capabilities and options for a broad range of industries on our website at https://www.pathward.com/commercial/.
About Pathward Financial, Inc.
Pathward Financial, Inc. (Nasdaq: CASH) is a U.S.-based financial holding company driven by its purpose to power financial inclusion. Through our subsidiary, Pathward®, N.A., we strive to increase financial availability, choice and opportunity across our Partner Solutions and Commercial Finance business lines. These strategic business lines provide support to individuals and businesses. Learn more at PathwardFinancial.com.
About Pathward®
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Globe and Mail
24 minutes ago
- Globe and Mail
Polycythemia Vera Market Expands as FDA Fast Tracks New Treatments and Clinical Trials Show Promising Results
The 7MM Polycythemia Vera market size reached approximately USD 1,900 million in 2024 and is projected to grow significantly through 2034. Key players such as Incyte/Novartis, PharmaEssentia/AOP Orphan Pharmaceuticals, Protagonist Therapeutics, Merck, Italfarmaco, Ionis Pharmaceutical, Silence Therapeutics, Perseus Proteomics, AbbVie, Johnson & Johnson Innovative Medicine, Mabwell (Shanghai) Bioscience and Disc Medicine, GluBio Therapeutics, and others are spearheading innovations. DelveInsight's report, titled ' Polycythemia Vera Market Insight, Epidemiology and Market Forecast -2034 ', provides a detailed assessment of historical and projected market trends from 2020 to 2034. The analysis encompasses epidemiology segmentation, treatment paradigms, emerging therapies, and competitive dynamics, offering stakeholders actionable insights into market opportunities and challenges. The report highlights how the anticipated introduction of targeted therapies and improved diagnostic tools will reshape the PV treatment landscape over the next decade. In 2024, the United States dominated the Polycythemia market, accounting for over 75% of the total market size, which amounts to USD 1.9 Billion across the 7MM. Among EU4 countries, Germany accounts for the maximum market size, while the United Kingdom occupies the bottom of the ladder in 2024. This trend is expected to continue reflecting disparities in treatment accessibility, Polycythemia Vera prevalence, and diagnostic rates across regions. Download the report to understand which factors are driving the Polycythemia Vera therapeutic market @ Polycythemia Vera Market Trends. The report also provides historical as well as forecasted PV epidemiology segmented by Total Prevalent Population of Polycythemia Vera, Prevalent Population of Polycythemia Vera Based on Symptoms, Gender-specific Prevalence of Polycythemia Vera, Prevalence of Polycythemia Vera by Gene Mutation, Prevalence of Polycythemia Vera Based on Risk, and Age-specific Prevalence of Polycythemia Vera in the 7MM. The report estimates that the 7MM had approximately 320,000 Polycythemia Vera cases in 2024, with numbers expected to rise steadily during the forecast period. Gender-specific data indicates that approximately 56% of the patient share in 7MM is attributed to males, whereas 44% are females. Additionally, across all races and ethnicities, the PV incidence is about 2.8 per 100,000 men and roughly 1.3 per 100,000 women. Discover evolving trends in Polycythemia Vera patient pool forecasts @ Polycythemia Vera Epidemiology Analysis. Recent Developments: In the latest financial statement, Incyte reported strong growth for Jakafi with net revenues of $773 million in Q4 2024 and $2.79 billion for the full year. In March 2025, Protagonist Therapeutics and Takeda announced positive topline results from the Phase 3 VERIFY study, where rusfertide met its primary and all secondary endpoints in treating polycythemia vera. These recent developments indicate positive momentum in the Polycythemia Vera treatment market. Rusfertide achieved a major milestone with the presentation of Phase 3 VERIFY trial results at the ASCO Annual Meeting in June 2025. The study met its primary endpoint and all key secondary endpoints, showing that rusfertide plus current standard of care more than doubled clinical response rates across high- and low-risk PV groups compared to placebo. In May 2025, the FDA granted Fast Track designation to givinostat, an orally administered histone deacetylase (HDAC) inhibitor for treating patients with polycythemia vera, highlighting givinostat's potential to make a meaningful difference. Learn more about the evolving trends in the Polycythemia Vera treatment market @ Polycythemia Vera Recent Developments. Polycythemia Vera management currently relies on a combination of treatments, including phlebotomy, cytoreductive agents such as hydroxyurea, and JAK inhibitors like JAKAFI (RUXOLITINIB) from Incyte/Novartis. Other notable medications used in the management of PV include BESREMi (PharmaEssentia/AOP Orphan Pharmaceuticals) and PEGASYS (pharmaand GmbH). Given its very different MoA compared to JAKAFI and BESREMi, rusfertide could become a viable alternative as an earlier line of therapy. In 2024, JAKAFI generated the highest revenue among these Polycythemia Vera therapies. While these therapies help manage symptoms and reduce thrombotic risks, they are associated with limitations including drug resistance, long-term toxicity, and inadequate control of disease progression. DelveInsight's report emphasizes that a significant number of patients experience suboptimal responses to existing treatments, highlighting a pressing need for novel mechanisms of action. The report highlights that the Polycythemia Vera pipeline features several investigational therapies across phases of development. Notable candidates include DIVESIRAN (Silence Therapeutics), PPMX-T003 (Perseus Proteomics), NAVITOCLAX (AbbVie), VAC85135 (Johnson & Johnson), 9MW3011/DISC-3405 (Mabwell), GLB-001 (GluBio Therapeutic) and others. Despite progress, challenges such as delayed diagnosis, treatment-related anemia, and lack of consensus on optimal monitoring strategies persist. DelveInsight's analysis identifies biomarker development and patient-centric drug delivery systems as key areas for innovation. Table of Contents 1. Key Insights 2. Report Introduction 3. Executive Summary 4. Polycythemia Vera Market Overview at a Glance 5. Epidemiology and Market Forecast Methodology 6. Key Events 7. Polycythemia Vera Background and Overview 8. Polycythemia Vera Treatment 9. Polycythemia Vera Epidemiology and Patient Population in the 7MM 10. Polycythemia Vera Patient Journey 11. Polycythemia Vera Marketed Drug 12. Polycythemia Vera Emerging Drugs 13. Polycythemia Vera: 7MM Analysis 14. Unmet needs 15. SWOT Analysis 16. KOL Views 17. Market Access and Reimbursement 18. Appendix 19. DelveInsight Capabilities 20. Disclaimer 21. About DelveInsight Related Reports Polycythemia Vera Pipeline Insight Polycythemia Vera Pipeline Insight provides comprehensive insights about the Polycythemia Vera pipeline landscape, pipeline drug profiles, including clinical and non-clinical stage products, and the Polycythemia Vera companies, including Silence Therapeutics, Ionis Pharmaceuticals, Perseus Proteomics, Kartos Therapeutics, and Disc Medicine among others. About DelveInsight DelveInsight is a leading market research and consulting firm specializing in disease-specific insights and therapeutic market analysis. Their reports integrate real-world data, clinical trial findings, and expert interviews to deliver comprehensive industry intelligence.
Globe and Mail
25 minutes ago
- Globe and Mail
How major US stock indexes fared Thursday, 7/31/2025
Stocks gave up early gains and closed lower on Wall Street, led by drops in health care companies. The S&P 500 fell 0.4% Thursday. The Dow Jones Industrial Average lost 0.7%, and the Nasdaq composite slipped less than 0.1%. Health care stocks sank after the White House released letters asking big pharmaceutical companies to cut prices and make other changes in the next 60 days. Meta Platforms surged after the parent company of Facebook and Instagram crushed Wall Street's sales and profit targets even as the company continues to pour billions of dollars into artificial intelligence. On Thursday: The S&P 500 fell 23.51 points, or 0.4%, to 6,339.39. The Dow Jones Industrial Average fell 330.30 points, or 0.7%, to 44,130.98. The Nasdaq composite fell 7.23 points, or less than 0.1%, to 21,122.45. The Russell 2000 index of smaller companies fell 20.75 points, or 0.9%, to 2,211.65. For the week: The S&P 500 is down 49.25 points, or 0.8%. The Dow is down 770.94 points, or 1.7%. The Nasdaq is up 14.13 points, or 0.1%. The Russell 2000 is down 49.42 points, or 2.2%. For the year: The S&P 500 is up 457.76 points, or 7.8%. The Dow is up 1,586.76 points, or 3.7%. The Nasdaq is up 1,811.66 points, or 9.4%. The Russell 2000 is down 18.51 points, or 0.8%.
CTV News
36 minutes ago
- CTV News
Trump increases tariff on Canada to 35% from 25%, cites fentanyl
WASHINGTON — U.S. President Donald Trump on Thursday signed an executive order increasing tariffs on Canadian goods to 35 per cent from 25 per cent on all products not covered by the U.S.-Mexico-Canada trade agreement, the White House said. Goods transshipped to another country to evade the new tariffs will be subject to a transshipment levy of 40 per cent, according to a White House fact sheet. The move - which Washington linked in part to what it said was Canada's failure to stop fentanyl smuggling - is the latest blow in a months-long tariff war which Trump initiated shortly after taking power. The announcement blaming Canada's 'continued inaction and retaliation' comes after Trump said Canadian Prime Minister Mark Carney reached out ahead of an Aug. 1 tariff deadline, but no conversations between the two took place. Trump had said any country failing to strike a deal with the U.S. before Friday will be subjected to higher tariffs imposed on goods. Carney's office did not immediately respond to a request for comment. Officials in Ottawa have repeatedly noted that only a miniscule amount of fentanyl entering the United States originates from Canada but they have already taken measures to strengthen the border. Carney said on Wednesday that the trade talks had been constructive but might not conclude by the deadline. He reiterated a deal removing all U.S. tariffs was unlikely. Carney has to coordinate his reaction with that of the 10 provinces, some of whom want a hard line and others who prefer a softer approach. Premier Doug Ford of Ontario, which accounts for around 40 per cent of Canadian GDP and is the country's industrial heartland, demanded Ottawa slap a 50 per cent counter tariff on imports of U.S. steel and aluminum. 'Canada shouldn't settle for anything less than the right deal. Now is not the time to roll over. We need to stand our ground,' he said in a post on X. Trump said that while he loved Canada, it had treated the United States 'very badly' for years. U.S. Commerce Secretary Howard Lutnick said Trump could reconsider the tariff if Carney 'starts turning on the charm and if he takes off his retaliation.' Earlier Thursday, Trump agreed to give Mexico a 90-day window to work toward a deal, allowing it to avoid a 30 per cent tariff that he threatened to impose by Aug. 1. Mexico will still have to pay a 25 per cent duty on U.S.-bound exports that are non USMCA-compliant, a tariff that Trump has linked to demands that Mexico do more to curb drug and human smuggling. Canada sends around 75 per cent of all its exports south of the border and is vulnerable to U.S. trade action. The increase in tariffs to 35 per cent will hit exports of steel, aluminum and automobiles and the products that are not compliant with the three-nation USMCA free trade deal. The economy has shown surprising resilience in the face of tariffs and is expected to avoid recession, economists say. About 90 per cent of Canadian exports to the U.S. in May were exempt under the USMCA. The compliance level has shot up dramatically in the last few months, while some companies have diversified exports to avoid tariffs. Canadian government data shows exports to the U.S. dropped by 10 percentage points to 68 per cent of total exports between May 2024 and May 2025, focused on manufacturing products such as cars and parts, and products made with steel and aluminum. Carney told reporters in June that if the two countries do not reach a trade deal by Aug. 1, Canada would likely impose more counter levies on U.S. exports of steel and aluminum. By Jasper Ward and Ryan Patrick Jones Additional reporting by David Ljunggren and Promit Mukherjee in Ottawa; Editing by Chizu Nomiyama and Stephen Coates.
